Par Pharmaceutical, Inc.

Member Case
Lead case is: 7:22-bk-22549

New York Southern Bankruptcy Court
Chapter 11
Judge:James L Garrity Jr
Case #: 7:22-bk-22546
Case Filed:Aug 16, 2022

TypeCorporation
# of Creditors10,001-25,000
Est. Assets$1,000,000,001 to $10 billion
Est. Liabilities $1,000,000,001 to $10 billion
Nature of Business Other
Nature of Debts Primarily Business

Debtor
Par Pharmaceutical, Inc.
6 Ram Ridge Rd
Chestnut Ridge, NY 10977-6713
Represented By
Paul D. Leake
Skadden, Arps, Slate, Meagher & Flom LLP
contact info
Last checked: never
U.S. Trustee
United States Trustee
Office of the United States Trustee U.S. Federal Office Building 201 Varick Street, Room 1006
New York, NY 10014


Docket last updated: 26 minutes ago
Tuesday, August 20, 2024
misc Close Adversary Proceeding Tue 08/20 11:40 AM
(Duplicate Case Entered in Error, see Case No. 24-7030 Adversary Case 7:24-ap-7029 Closed. (Bush, Brent)
Related: [-]
Friday, August 16, 2024
20 20 cmp Complaint (fee) Fri 08/16 8:06 PM
Adversary case 24-07029 Complaint against TPG Capital, L.P., TPG Global, LLC, TPG VI Management, LLC, TPG Partners VI, L.P., TPG Biotechnology Partners IV, L.P., TPG Advisors V, Inc.., TPG ADVISORS VI, INC., TPG BIOTECHNOLOGY GENPAR IV, L.P., TPG GENPAR VI, L.P,, TPG SKY L.P., TPG SKY CO-INVEST L.P., TPG BIOTECHNOLOGY PARTNERS IV L.P., PARK STREET INVESTORS L.P., Paul Victor Campanelli, Thomas Joseph Haughey, Terrance Coughlin, Patrick LePore, BARRY J. GILMAN, JOSEPH A. BARBARITE, CHAD M. GASSERT, STEPHEN O. MONTALTO, ANTONIO PERA, MUTHUSAMY SHANMUGAM, Stephen Carey, SUKETU P. SANGHVI, LAWRENCE MILTON BROWN, PHILLIP JOHN BRANCAZIO, DIANE MONTALTO, SHARAD MANSUKANI, KEITH A. KUCINSKI, MICHAEL J. ALTAMURO, MARTIN L. WILSON, KAREN A. OCONNOR, JOHN L. AMERES, HYUN SOO HONG, ANH TRANCAO, JOHN DOE 1-999 (Fee Amount $ 350.). Nature(s) of Suit: (14 (Recovery of money/property - other)) Filed by Shireen Barday, Duane L. Loft, Anastasia Cembrovska, Ashley B Mullen on behalf of Matthew Dundon, Trustee of the Endo GUC Trust. (Loft, Duane)
Related: [-]
Tuesday, June 25, 2024
19 19 misc Chapter 11 Monthly Operating Report UST Form 11-MOR Tue 06/25 9:34 PM
Chapter 11 Monthly Operating Report for the Month Ending: 03/31/2024 Filed by Andrew Matott on behalf of Par Pharmaceutical, Inc.. (Matott, Andrew)
Related: [-]
Friday, December 29, 2023
18 18 notice Notice, Withdrawal Fri 12/29 10:16 AM
Notice of Withdrawal of Notice of Appearance Related [+] filed by Sean P Williams on behalf of Ford Motor Credit Company, LLC. (Williams, Sean)
Related: [-] 17
Thursday, December 28, 2023
17 17 notice Notice, Appearance Thu 12/28 12:02 PM
Notice of Appearance filed by Sean P Williams on behalf of Ford Motor Credit Company, LLC. (Williams, Sean)
Related: [-]
Wednesday, April 26, 2023
16 16 misc Amended Schedules Wed 04/26 3:21 PM
Amended Schedules filed: Schedule A/B - Non-Individual, Schedule D - Non-Individual, Schedule E/F - Non-Individual, Schedule G - Non-Individual Filed by Kyle J. Ortiz on behalf of Par Pharmaceutical, Inc.. (Ortiz, Kyle)
Related: [-]
crditcrd Auto - docket of credit card Wed 04/26 4:07 PM
Receipt of Amended Schedules([LINK 22-22546 jlg] ) [misc,schaja] ( 32.00) Filing Fee. Receipt number A16178940. Fee amount 32.00. Related [+] (U.S. Treasury)
Related: [-] Doc #16
Friday, March 03, 2023
15 15 misc Disclosure of Compensation of Attorney For Debtor (Rule 2016(b)) - Form 2030 Fri 03/03 1:15 PM
Disclosure of Compensation of Attorney For Debtor (Rule 2016(b))- Form 2030 Filed by Paul D. Leake on behalf of Par Pharmaceutical, Inc.. (Leake, Paul)
Related: [-]
Tuesday, February 28, 2023
misc Terminate Pending Deadlines Tue 02/28 2:21 PM
Pending Deadlines Terminated. (Rodriguez, Willie)
Related: [-]
Monday, February 27, 2023
misc Terminate Pending Deadlines Mon 02/27 3:45 PM
Pending Deadlines Terminated: Schedules (Rodriguez, Willie)
Related: [-]
Thursday, November 17, 2022
14 14 order Motion, Extend Deadline to File Schedules Thu 11/17 9:31 AM
Order signed on 11/16/2022 Granting Motion To Extend Deadline to File Schedules or Provide Required Information: DEADLINE: 11/30/2022 Related [+] (Rodriguez, Willie)
Related: [-] 11
Thursday, November 10, 2022
13 13 misc Statement of Financial Affairs Thu 11/10 4:57 PM
Statement of Financial Affairs - Non-Individual /Global Notes and Statement of Financial Affairs for Par Pharmaceutical, Inc. Filed by Kyle J. Ortiz on behalf of Par Pharmaceutical, Inc.. (Ortiz, Kyle)
Related: [-]
12 12 misc Schedules Thu 11/10 4:56 PM
Schedules filed: Schedule A/B - Non-Individual, Schedule D - Non-Individual, Schedule E/F - Non-Individual, Schedule G - Non-Individual, Schedule H - Non-Individual /Global Notes, Summary and Schedules of Assets and Liabilities for Par Pharmaceutical, Inc. Filed by Kyle J. Ortiz on behalf of Par Pharmaceutical, Inc.. (Ortiz, Kyle)
Related: [-]
Thursday, October 27, 2022
11 11 motion Motion, Extend Deadline to File Schedules Thu 10/27 1:18 PM
Motion to Extend Deadline to File Schedules or Provide Required Information /(Hearing Date: 11/10/2022 at 11:00 AM, Objections Due: 11/3/2022 at 4:00 PM) Notice of Hearing and Motion of Debtors for Entry of an Order Further Extending Time to File Schedules of Assets and Liabilities and Statements of Financial Affairs (Attachment: Exhibit A: Proposed Order) filed by Kyle J. Ortiz on behalf of Par Pharmaceutical, Inc. with hearing to be held on 11/10/2022 at 11:00 AM at Videoconference (ZoomGov) (JLG) Objections due by 11/3/2022,. (Ortiz, Kyle)
Related: [-]
Monday, October 24, 2022
10 10 order Motion, Extend Deadline to File Schedules Mon 10/24 5:47 PM
Order signed on 10/24/2022 Granting Motion To Extend Deadline to File Schedules or Provide Required Information. Deadline: 10/31/2022 Related [+] (Rodriguez, Willie)
Related: [-] 9
Tuesday, September 27, 2022
9 9 motion Motion, Extend Deadline to File Schedules Tue 09/27 3:09 PM
Motion to Extend Deadline to File Schedules or Provide Required Information /(Hearing Date: October 13, 2022 at 11:00 a.m., Objection Deadline: October 6, 2022 at 4:00 p.m.) Notice of Hearing and Motion of Debtors for Entry of an Order Extending Time to File Schedules of Assets and Liabilities and Statements of Financial Affairs filed by Kyle J. Ortiz on behalf of Par Pharmaceutical, Inc. with hearing to be held on 10/13/2022 at 11:00 AM at Videoconference (ZoomGov) (JLG) Objections due by 10/6/2022,. (Ortiz, Kyle)
Related: [-]
Monday, September 12, 2022
misc Add Party Mon 09/12 9:41 AM
Party Kroll Restructuring Administration LLC Claims Agent added to the case.. (Rodriguez, Willie)
Related: [-]
Friday, September 09, 2022
8 8 6 pgs order Order Re: Motion, Appoint Claims and Noticing Agent Fri 09/09 9:11 AM
Order signed on 9/6/2022 Granting Motion Appointing Kroll Restructuring Administration LLC as Claims and Noticing Agent. Related [+] (Rodriguez, Willie)
Related: [-] 6
Thursday, August 25, 2022
7 7 order Motion, Extend Deadline to File Schedules Thu 08/25 3:40 PM
Order signed on 8/23/2022 Granting Motion To Extend Deadline to File Schedules or Provide Required Information. Deadline: 9/29/2022 Related [+] (Rodriguez, Willie)
Related: [-] 3
Thursday, August 18, 2022
6 6 motion Motion, Appoint Claims and Noticing Agent Thu 08/18 7:18 PM
Motion to Appoint Kroll Restructuring Administration LLC as Claims and Noticing Agent /Application of the Debtors for an Order (I) Appointing Kroll Restructuring Administration LLC as Claims and Noticing Agent Nunc Pro Tunc to the Petition Date; and (II) Granting Related Relief filed by Paul D. Leake on behalf of Par Pharmaceutical, Inc.. (Leake, Paul)
Related: [-]
misc Case Association - Joint Administration Thu 08/18 4:04 PM
Case Jointly Administered with 22-22549 (Rodriguez, Willie)
Related: [-]
Wednesday, August 17, 2022
5 5 order Motion, Joint Administration Wed 08/17 6:37 PM
An order has been entered on 8/17/2022 in accordance with Rule 1015(b) of the Federal Rules of Bankruptcy Procedure directing the procedural consolidation and joint administration of the chapter 11 cases of Endo International plc and its affiliates that have concurrently commenced chapter 11 cases. The docket in the chapter 11 case of Endo International plc (3755), Case No. 22-22549 (JLG), should be consulted for all matters affecting the chapter 11 cases of: 70 Maple Avenue, LLC (1491); Actient Pharmaceuticals LLC (7232); Actient Therapeutics LLC (2019); Anchen Incorporated (8760); Anchen Pharmaceuticals, Inc. (9179); Astora Womens Health Ireland Limited (5829); Astora Womens Health, LLC (0427); Auxilium International Holdings, LLC (9643); Auxilium Pharmaceuticals, LLC (6883); Auxilium US Holdings, LLC (8967); Bermuda Acquisition Management Limited (N/A); BioSpecifics Technologies LLC (4851); Branded Operations Holdings, Inc. (6945); DAVA International, LLC (9945); DAVA Pharmaceuticals, LLC (7354); Endo Aesthetics LLC (0218); Endo Bermuda Finance Limited (4093); Endo Designated Activity Company (7135); Endo Eurofin Unlimited Company (2009); Endo Finance IV Unlimited Company (2779); Endo Finance LLC (6481); Endo Finance Operations LLC (6355); Endo Finco Inc. (5794); Endo Generics Holdings, Inc. (4834); Endo Global Aesthetics Limited (2898); Endo Global Biologics Limited (2735); Endo Global Development Limited (4785); Endo Global Finance LLC (7754); Endo Global Ventures (4244); Endo Health Solutions Inc. (2871); Endo Innovation Valera, LLC (3622); Endo Ireland Finance II Limited (0535); Endo LLC (6640); Endo Luxembourg Finance Company I S. r.l. (3863); Endo Luxembourg Holding Company S..r.l. (7168); Endo Luxembourg International Financing S..r.l. (2905); Endo Management Limited (4866); Endo Par Innovation Company, LLC (2435); Endo Pharmaceuticals Finance LLC (5768); Endo Pharmaceuticals Inc. (5829); Endo Pharmaceuticals Solutions Inc. (7911); Endo Pharmaceuticals Valera Inc. (9931); Endo Procurement Operations Limited (7840); Endo TopFin Limited (8086); Endo U.S. Inc. (0786); Endo US Holdings Luxembourg I S..r.l. (7910); Endo Ventures Aesthetics Limited (9967); Endo Ventures Bermuda Limited (0688); Endo Ventures Cyprus Limited (1544); Endo Ventures Limited (6029); Generics Bidco I, LLC (6905); Generics International (US) 2, Inc. (5075); Generics International (US), Inc. (6489); Generics International Ventures Enterprises LLC (4685); Hawk Acquisition Ireland Limited (4776); Innoteq, Inc. (3381); JHP Acquisition, LLC (7861); JHP Group Holdings, LLC (7688); Kali Laboratories 2, Inc. (6751); Kali Laboratories, LLC (4898); Luxembourg Endo Specialty Pharmaceuticals Holding I S. r.l. (0601); Moores Mill Properties L.L.C. (9523); Paladin Labs Canadian Holding Inc. (N/A); Paladin Labs Inc. (1410); Par Laboratories Europe, Ltd. (9597); Par Pharmaceutical 2, Inc. (4895); Par Pharmaceutical Companies, Inc. (8301); Par Pharmaceutical Holdings, Inc. (3135); Par Pharmaceutical, Inc. (8342); Par Sterile Products, LLC (0105); Par, LLC (1286); Quartz Specialty Pharmaceuticals, LLC (5368); Slate Pharmaceuticals, LLC (6201); Timm Medical Holdings, LLC (8744); and Vintage Pharmaceuticals, LLC (7882) Related [+] (Rodriguez, Willie)
Related: [-] 2
4 4 misc Affidavit Pursuant to LR 1007-2 Wed 08/17 5:49 PM
Affidavit Pursuant to LR 1007-2 //Declaration of Mark Bradley in Support of Chapter 11 Petitions and First Day Papers Filed by Paul D. Leake on behalf of Par Pharmaceutical, Inc.. (Leake, Paul)
Related: [-]
3 3 motion Motion, Extend Deadline to File Schedules Wed 08/17 9:43 AM
Motion to Extend Deadline to File Schedules or Provide Required Information /Motion of the Debtors for Entry of an Order (I) Extending the Time to File Schedules and Statements of Financial Affairs; (II) Extending the Time to File Reports of Financial Information Required Under Bankruptcy Rule 2015.3; (III) Waiving Requirement to File List of Equity Security Holders and Provide Notice of Commencement to Equity Security Holders; and (IV) Granting Related Relief filed by Paul D. Leake on behalf of Par Pharmaceutical, Inc.. (Leake, Paul)
Related: [-]
2 2 motion Motion, Joint Administration Wed 08/17 12:05 AM
Motion for Joint Administration /Motion of the Debtors for Entry of an Order (I) Directing Joint Administration of the Chapter 11 Cases Pursuant to Bankruptcy Rule 1015(b); (II) Waiving the Requirements of Section 342(c)(1) of the Bankruptcy Code and Bankruptcy Rule 2002(n); and (III) Granting Related Relief filed by Paul D. Leake on behalf of Par Pharmaceutical, Inc.. (Leake, Paul)
Related: [-]
misc Add Judge Wed 08/17 7:49 AM
Judge James L. Garrity, Jr. added to the case. (Cappiello, Karen)
Related: [-]
misc Set Deficiency Deadlines Wed 08/17 10:21 AM
Deficiencies Set: Section 521(i) Incomplete Filing Date: 9/30/2022. Schedule A/B due 8/30/2022. Schedule D due 8/30/2022. Schedule E/F due 8/30/2022. Schedule G due 8/30/2022. Schedule H due 8/30/2022. Summary of Assets and Liabilities due 8/30/2022. Statement of Financial Affairs due 8/30/2022. Atty Disclosure State. due 8/30/2022. Corporate Resolution due 8/30/2022. Local Rule 1007-2 Affidavit due by: 8/30/2022. Incomplete Filings due by 8/30/2022, (Walker, Justin)
Related: [-]
misc Set Deficiency Deadlines Wed 08/17 10:58 AM
Deficiencies Set: Section 521(i) Incomplete Filing Date: 9/30/2022. List of all creditors due 8/30/2022. List of All Creditors Required on Case Docket in PDF Format due 8/30/2022. Incomplete Filings due by 8/30/2022, (Walker, Justin)
Related: [-]
misc Terminate Pending Deadlines Wed 08/17 3:59 PM
Pending Deadlines Terminated. (Walker, Justin)
Related: [-]
Tuesday, August 16, 2022
1 1 24 pgs misc Voluntary Petition (Chapter 11) Tue 08/16 9:49 PM
Chapter 11 Voluntary Petition for Non-Individual. Order for Relief Entered. Case Designated As Mega as per LBR 1073-1. Chapter 11 Plan due by 12/14/2022, Disclosure Statement due by 12/14/2022, Initial Case Conference due by 9/15/2022, Filed by Paul D. Leake of Skadden, Arps, Slate, Meagher & Flom LLP on behalf of Par Pharmaceutical, Inc.. (Leake, Paul)
Related: [-]
crditcrd Auto - docket of credit card Tue 08/16 11:25 PM
Receipt of Voluntary Petition (Chapter 11)([LINK 22-22546 ) [misc,824] (1738.00) Filing Fee. Receipt number A15881001. Fee amount 1738.00. Related [+] (U.S. Treasury)
Related: [-] Doc #1